· Published by Health Canada · Official notice
This is duplicated text of a letter from Bristol-Myers Squibb Canada. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
September 3, 2013
Dear Healthcare Professional:
Please distribute this Notice to the Hospital Chief of Staff and post it in your institution.
Subject: BiCNUFootnote 1 (carmustine for injection U.S.P.) Lyophilized Powder, 100 mg/vial DIN 00297763
Shortage of Canadian labeled BiCNU and replacement with U.S. labeled stock
| Component | Lot | Expiry |
|---|---|---|
| Carmustine vial | CMCA3002 | 02/16 |
| Diluent Ampule | 2130 | 09/15 |
| Kit | 2C7010A | 09/15 |
This temporary measure has been taken, with Health Canada's authorization, in order to ensure patients have uninterrupted access to BiCNU until supplies of Canadian labeled product are replenished. This measure is expected to last until October 2013.
Please note that while in Canada, BiCNU (carmustine) is sold under the BMS Canada label, in the U.S., BiCNU is sold under the Heritage Pharmaceuticals Inc. label.
BMS wishes to confirm that, with the exception of the labeling, the BiCNU (carmustine) vials and diluent ampules supplied in the U.S. labeled trade packs are identical to those currently distributed on the Canadian marketplace.
As there are some differences in the product labeling, BMS also wishes to remind you that the U.S. labeled product must be used in accordance with the recommendations outlined in the Canadian Prescribing Information (PI) for BiCNU dated 30 June 2011. In particular, the approved Canadian dosing recommendations outlined below should be strictly adhered to:
The full Canadian PM for BiCNU, prepared for health professionals can be found at: www.bmscanada.ca or by contacting Bristol-Myers Squibb Canada at 1-866-463-6267. In addition, to ensure rapid access to the Canadian labeled recommendations, the Canadian PI is included in each shipment of U.S. labeled BiCNU. As a reminder, in Canada, BiCNU (carmustine) is indicated as palliative therapy to surgery and radiotherapy or in combination therapy with other chemotherapeutic agents in primary brain tumors, malignant lymphomas, multiple myeloma, malignant melanoma (disseminated) and gastrointestinal carcinoma.
Managing marketed health product-related adverse reactions depends on healthcare professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any serious or unexpected adverse reactions possibly related to the use of BiCNU should be reported to Bristol-Myers Squibb Canada or Health Canada at the following addresses:
Bristol-Myers Squibb Canada
2344 Alfred-Nobel, suite 300
Montréal, Québec
H4S 0A4
Tel : 866-463-6267
You can also report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate
E-mail: GMP_Questions_BPF@hc-sc.gc.ca
Telephone: 613-957-1492
Fax: 613-957-6709
If you have any questions regarding this communication, please contact Customer Services at 1-800-267-0005 (8:30 a.m. to 5:00 p.m. Eastern Standard Time). For medical queries, please call Medical Services at 1-866-463-6267.
Original signed by
Vicky Esposito
VIce-President, Regulatory Affairs & QA;
TM of Bristol-Myers Squibb Company used under licence by Bristol-Myers Squibb Canada